Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (13688)	5/28/2000 5:34:00 AM
From: Arthur Radley	Respond to of 17367

With this incessant debate over my "favorite" off-shore biotech, run by a bunch of scalawags, I offer the following product to those who have to continually debate the "true-believers" who think that Xoma has a future. To deflect some of the constant and repetitive blathering you need......http://zapatopi.net/afdb.html

To: Cacaito who wrote (13688)	5/28/2000 10:58:00 AM
From: Bluegreen	Read Replies (2) \| Respond to of 17367

Cacaito, what is this worth if approved??????>>>>>>>>XOMA Initiates Phase I/II Clinical Study of Anti-CD11a in Kidney Transplant Patients BERKELEY, Calif.--(BW HealthWire)--March 30, 2000--XOMA Ltd. (Nasdaq:XOMA) today announced the initiation of a Phase I/II clinical study of anti-CD11a in kidney transplant recipients. XOMA is collaborating with Genentech, Inc. (NYSE:DNA) to develop this recombinant, humanized monoclonal antibody designed to selectively inhibit immune system T cells. This is the second indication being evaluated for this investigational antibody; a Phase III trial of anti-CD11a in patients with moderate-to-severe plaque psoriasis began in December 1999. "T cells are involved in the immune system's rejection of transplanted organs as well as in autoimmune diseases like psoriasis," said Marvin Garovoy, MD, Vice President of Clinical and Medical Affairs at XOMA. "We believe that anti-CD11a may have potential advantages over immunosuppressive drugs currently used to prevent organ transplant rejection. Initially, we will study the antibody in combination with standard immunosuppressive drugs to test its safety in this population and to see if it further reduces graft rejection. Ultimately, anti-CD11a may allow reduced use of other agents, potentially making for a safer and more effective therapeutic regimen."<<<<<<<<<<<

To: Cacaito who wrote (13688)	5/28/2000 11:05:00 AM
From: aknahow	Respond to of 17367

<<<How quickly Gw forgot total mortality! >>>> Cacaito, Target was 34 and trial halted one short or at 33. This is my recollection and I have not bothered to check. This link discusses E. Coli and endotoxin. I do accept your exotoxin explanation but am a bit confused as to why endotoxin is referred to. Is HUS only a problem with E. Coli 157 ???

To: Cacaito who wrote (13688)	5/28/2000 5:30:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

Cacaito, if forced to choose between trusting the judgment of the Canadian government and your, I would choose your judgment. Why would this new antibiotic bind an exotoxin? why would it be better than antibiotics already being used? Your post seemend clear that antibiotics were not the solution. Clarify what is going on if you have time. Thanks. By: bluechiphl Reply To: 1183 by juliarakova Sunday, 28 May 2000 at 12:38 PM EDT Post # of 1184 THE CANADIAN GOVERNMENT HAS RUSHED AN UNAPPROVED DRUG FOR ECOLI MADE BY SYNSORB[SYBB] BECAUSE OF A SERIOUS OUTBREAK OF ECOLI. THIS IN ITSELF IS A TERRIFIC VERIFICATION OF THE SYNSORB PRODUCT IN PHASE III TRIALS. WHAT DO YOU THINK MANNY?

To: Cacaito who wrote (13688)	5/28/2000 6:02:00 PM
From: Bluegreen	Read Replies (2) \| Respond to of 17367

Cacaito, break out the Peptobismol while I tell my opinions on Baxter. They and several other Pharms looked at Neuprex. Makes no sense for Baxter to pluck down ten million IF they didn't think it works. Irregardless of trial situation it either works or it doesn't. Baxter figures it works and that they will find a way to get it approved. You stating that all they wanted for their 10 million was to see if it got Meningo. through doesn't make sense!!!!! If it got approved and didn't work WHAT GOOD IS THAT FOR 10 MILLION!!!! Would that be smart of Baxter? Get a drug approved that doesn't work??? Why would Baxter touch a drug that didn't work??? I can only hope that Xoma goes below 3 or 2 a share. And guess what? In my opinion I am not the only one who thinks that way. In the meantime it is up to Baxter to ram through Neuprex in ANY way it can. Why? Wouldn't it be a miracle if it DIDN'T work??? ONE MORE THING. I have followed both Baxter and Xoma.......let me tell you in the strongest terms XOMA IS NO BAXTER!!!!! As in XOMA is NO DNA! BASTA YA!!!!! BASTA YA!!!!